Development of anticancer drugs and gene therapies

Stéphane Gagné
CEO, Co-founder
Brigitte Lemieux
Marketing Director, Co-founder
Kathie Béland
Research Director, Co-founder

Immugenia Inc. is developing the next generation of CAR-T therapy to treat and prevent relapses in hematological and solid cancers. This is achieved by engineering the patients’ hematopoietic stem cells and leveraging their synergistic activity. This provides patients with a one-and-done treatment to fight hard-to-treat cancers and prevent relapses.

Together, let’s build the world of tomorrow.